Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

NCT03822117 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
111
Enrollment
INDUSTRY
Sponsor class

Stopped A business decision was made to to discontinue further enrollment. There were no safety concerns that contributed to this decision.

Conditions

Interventions

Sponsor

Incyte Corporation